Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NGLWcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz6[mY2UUN3ME2wMlAxODR3ODDuUS=> NILZOpBUSU6JRWK=
ES4 NHvQZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;ZVWlEPTB;MD6wNFA3PTNibl2= Mkf1V2FPT0WU
ACHN M1jrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe4e3lTUUN3ME2wMlAxODh6NzDuUS=> MoHzV2FPT0WU
KYSE-510 NH3CfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETIb|RKSzVyPUCuNFAxQTd3IH7N MUnTRW5ITVJ?
EW-7 NYDJWlJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDWTWM2OD1yLkCwNlU5KG6P MV7TRW5ITVJ?
BFTC-905 NXTwNZF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LqdmlEPTB;MD6wNFUyPSCwTR?= M{nH[3NCVkeHUh?=
KE-37 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W4[WlEPTB;MD6wNFU3OSCwTR?= MXzTRW5ITVJ?
SBC-5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;Vc2lEPTB;MD6wNFU4KG6P MX;TRW5ITVJ?
NKM-1 M37HT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\2SYltUUN3ME2wMlAxPzB7IH7N Mn;0V2FPT0WU
RH-1 NHT6PHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:3dplKSzVyPUCuNFA4OThibl2= M1XCdXNCVkeHUh?=
ALL-PO NFzIdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHySIFKSzVyPUCuNFA5OyCwTR?= MXvTRW5ITVJ?
QIMR-WIL M2[3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEC4PVQhdk1? NEW2TYVUSU6JRWK=
A375 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7lTWM2OD1yLkCwPVk2KG6P MUPTRW5ITVJ?
SIG-M5 M3mw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEGwOEBvVQ>? NYrWUWRUW0GQR1XS
KGN NYXVU|JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMEGwPEBvVQ>? NWjDRmd7W0GQR1XS
EW-13 NYrBOWV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO0TWM2OD1yLkCxNVIhdk1? M3P1dHNCVkeHUh?=
NCI-SNU-1 NFfqPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XCZ2lEPTB;MD6wNVYhdk1? MYfTRW5ITVJ?
PSN1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XVWWlEPTB;MD6wNVY2KG6P NFTUb5RUSU6JRWK=
HUTU-80 NYXtTm1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMEG2OkBvVQ>? MnTUV2FPT0WU
EW-16 M3nQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvr[Xd1UUN3ME2wMlAzOyCwTR?= MnnGV2FPT0WU
786-0 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LmcGlEPTB;MD6wNlMhdk1? M{mxb3NCVkeHUh?=
ES1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPRTWM2OD1yLkCyOlghdk1? NELqTYtUSU6JRWK=
RKO MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS3c|lKSzVyPUCuNFI4QSCwTR?= M2[3[3NCVkeHUh?=
ESS-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof0TWM2OD1yLkCyPFYhdk1? NV2xVoV2W0GQR1XS
SK-UT-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzLOmNKSzVyPUCuNFI6PyCwTR?= MYPTRW5ITVJ?
LB2241-RCC NFHpeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\DPJBKSzVyPUCuNFMyQCCwTR?= NVHjRYs1W0GQR1XS
CHL-1 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXlV2JKSzVyPUCuNFMzPCCwTR?= NFTodpBUSU6JRWK=
SW1783 NH2wdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\yTGlEPTB;MD6wN|M3KG6P MofoV2FPT0WU
MEL-JUSO M{i2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMEO5NUBvVQ>? NHjUV2xUSU6JRWK=
HT-29 NXrZcJR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HlcGlEPTB;MD6wOFE{KG6P NVLTfFVZW0GQR1XS
SNG-M M4jJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMESyOUBvVQ>? NIDmXIRUSU6JRWK=
TE-15 NH\NNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTQTWM2OD1yLkC0OlQhdk1? Mln1V2FPT0WU
HOS NFrqW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjZTWM2OD1yLkC0PEBvVQ>? NFLBTY1USU6JRWK=
BB65-RCC NF;QSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3njTWlEPTB;MD6wOVEzKG6P Mn3JV2FPT0WU
HCE-4 NY[3NYdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX2TWM2OD1yLkC1Nlghdk1? NXiwW256W0GQR1XS
MHH-ES-1 NGC3dlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMEWzNUBvVQ>? MXTTRW5ITVJ?
RPMI-7951 NVnCd212T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\lTWM2OD1yLkC1OFEhdk1? M4\ONnNCVkeHUh?=
IST-SL2 MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlriTWM2OD1yLkC1PFQhdk1? NWLjeG5YW0GQR1XS
CMK NXTuOGdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv1dnZ{UUN3ME2wMlA2QDZibl2= Mm\HV2FPT0WU
GR-ST MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLFPIpUUUN3ME2wMlA2QTVibl2= MUnTRW5ITVJ?
NALM-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7lW|NKSzVyPUCuNFYzOiCwTR?= NITSUpJUSU6JRWK=
RPMI-6666 MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nZN2lEPTB;MD6wOlUzKG6P NV\sRZpPW0GQR1XS
LC-2-ad Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nlemlEPTB;MD6wOlU{KG6P NULMSoZLW0GQR1XS
ARH-77 NVrHe5hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPITWM2OD1yLkC3NVEhdk1? MVfTRW5ITVJ?
IST-MEL1 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEeyOkBvVQ>? NW\5XIN3W0GQR1XS
SW1710 M1TaU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfXcFRHUUN3ME2wMlA4PTFibl2= NVn6ephWW0GQR1XS
DEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fuTWlEPTB;MD6wPFg4KG6P MVXTRW5ITVJ?
AGS NWi4TGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn6bYNKSzVyPUCuNFkxOiCwTR?= M2jXXXNCVkeHUh?=
NCI-H2122 NFn6RpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEm0OkBvVQ>? M3;tfnNCVkeHUh?=
HSC-4 M4PDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSxbmZKSzVyPUCuNVAzKG6P NX\H[XpIW0GQR1XS
AM-38 M2XQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPXb3JKSzVyPUCuNVIyKG6P NXHPWlNQW0GQR1XS
769-P NXKzUHM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXJdpNvUUN3ME2wMlEzOyCwTR?= NXXGVVFDW0GQR1XS
RT-112 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjsZYFtUUN3ME2wMlEzPyCwTR?= M{PsN3NCVkeHUh?=
MCF7 MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jPd2lEPTB;MD6xN|Yhdk1? NF\HSWNUSU6JRWK=
IGROV-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\SPJdKSzVyPUCuNVQ2KG6P M4fR[XNCVkeHUh?=
OCI-AML2 MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXQNXVKSzVyPUCuNVQ4KG6P NW\5ZnhLW0GQR1XS
NCI-H1299 MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjsNFFKSzVyPUCuNVU4KG6P MmW4V2FPT0WU
A431 MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DnZ2lEPTB;MD6xPFMhdk1? MoPLV2FPT0WU
SW982 NVyyVnlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW4XmFKSzVyPUCuNlE{KG6P NU\OWHZbW0GQR1XS
BB30-HNC MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXpO2NKSzVyPUCuNlMyKG6P M13Yb3NCVkeHUh?=
ACN MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjVTWM2OD1yLkK0OEBvVQ>? MVzTRW5ITVJ?
647-V MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknNTWM2OD1yLkK0PEBvVQ>? M1vsd3NCVkeHUh?=
SK-PN-DW NW\wOIxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMk[2JI5O NXvFWol1W0GQR1XS
LCLC-97TM1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTpb3BKSzVyPUCuNlY4KG6P M3\OfXNCVkeHUh?=
LB1047-RCC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPNTWM2OD1yLkK2PUBvVQ>? NGK1U4dUSU6JRWK=
A2780 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;6R2lEPTB;MD6yO{BvVQ>? NF\YbnVUSU6JRWK=
C-33-A NIKx[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMkezJI5O MlX4V2FPT0WU
NCI-H2228 NVXXVHFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;Z[4xJUUN3ME2wMlMyPCCwTR?= M3HCNHNCVkeHUh?=
TE-5 NHHXcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojzTWM2OD1yLkOxOkBvVQ>? Mo\CV2FPT0WU
HC-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwM{K3JI5O MVXTRW5ITVJ?
SK-MES-1 NXK0NoQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj4NHVGUUN3ME2wMlMzQCCwTR?= NIm4[45USU6JRWK=
NCI-H1355 M3HTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojXTWM2OD1yLkO4NUBvVQ>? NYrweHBZW0GQR1XS
YKG-1 M{WzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjsW21KSzVyPUCuOFE6KG6P MWnTRW5ITVJ?
RS4-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLmc5F1UUN3ME2wMlQ{OyCwTR?= NHnaZXZUSU6JRWK=
Daoy NUHwTWVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInTdmlKSzVyPUCuOFU3KG6P MofwV2FPT0WU
A3-KAW M2jLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG3TWM2OD1yLkW1NUBvVQ>? NUDHVVR6W0GQR1XS
SK-MEL-30 MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnZNoQ5UUN3ME2wMlU2PCCwTR?= MXXTRW5ITVJ?
U031 MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHRc2JKSzVyPUCuOVY2KG6P MVfTRW5ITVJ?
SK-LMS-1 NFPTPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwNUe4JI5O NYTzVVFoW0GQR1XS
ES6 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwNUi2JI5O MmP3V2FPT0WU
EoL-1-cell M2fRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrmXFRjUUN3ME2wMlYyPiCwTR?= MUfTRW5ITVJ?
NCI-H2009 NXjwN4hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPjTWM2OD1yLk[xPUBvVQ>? NID3dpZUSU6JRWK=
A4-Fuk MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\YTWM2OD1yLk[yOkBvVQ>? M4jjW3NCVkeHUh?=
KYSE-270 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXBe3pKSzVyPUCuOlM1KG6P MX;TRW5ITVJ?
SK-LU-1 MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G2fmlEPTB;MD62OVUhdk1? MmG5V2FPT0WU
SW872 M3Kyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13ifmlEPTB;MD63OlUhdk1? MXzTRW5ITVJ?
ES8 MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwN{igcm0> M3WxT3NCVkeHUh?=
G-402 M4TifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\lTWM2OD1yLke4OEBvVQ>? NIS2empUSU6JRWK=
ATN-1 M{m4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;zTWM2OD1yLkiwO{BvVQ>? NEL4eXFUSU6JRWK=
DoTc2-4510 NEPSTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwOUCxJI5O MWDTRW5ITVJ?
MES-SA MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\wSWlEPTB;MD65NFUhdk1? MljOV2FPT0WU
SF268 NYG2S3hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWCz[Wk6UUN3ME2wMlkzPyCwTR?= M37TSHNCVkeHUh?=
SF539 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\xVmRVUUN3ME2xMlAzKG6P NIPvUoZUSU6JRWK=
NB69 NWTBd|R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFwMEWgcm0> MYPTRW5ITVJ?
8505C MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPUTWM2OD1zLkC2JI5O Mlr2V2FPT0WU
CAL-12T MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITqU|BKSzVyPUGuNFghdk1? M{jDWHNCVkeHUh?=
BHY MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofJTWM2OD1zLkG0JI5O MVXTRW5ITVJ?
LB647-SCLC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HGU2lEPTB;MT6xPEBvVQ>? MnXHV2FPT0WU
CAL-62 NVLCcm5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwMkKgcm0> Ml:5V2FPT0WU
MEG-01 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\jO2lEPTB;MT6yO{BvVQ>? MmP0V2FPT0WU
MG-63 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q5cGlEPTB;MT6zN{BvVQ>? MYPTRW5ITVJ?
SW620 NH75cZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXB[ohxUUN3ME2xMlM2KG6P M1rrUHNCVkeHUh?=
A388 NYW1eZR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\nPXVKSzVyPUGuN|Yhdk1? NEf2UppUSU6JRWK=
BCPAP NWjFW4kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF25S2FKSzVyPUGuOFUhdk1? NVi0W2VXW0GQR1XS
P30-OHK NVLRUJJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLhTWM2OD1zLkS2JI5O NVm0[4h7W0GQR1XS
Ca9-22 M1e0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPUTFFWUUN3ME2xMlU1KG6P NF2xemZUSU6JRWK=
VMRC-RCZ M4\mT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoniTWM2OD1zLkW0JI5O NUXNXFF1W0GQR1XS
LOXIMVI MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInHc49KSzVyPUGuOkBvVQ>? NX;wPZlXW0GQR1XS
L-540 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwNjDuUS=> M1e1S3NCVkeHUh?=
NTERA-S-cl-D1 M4jRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPDRWRNUUN3ME2xMlY1KG6P MUPTRW5ITVJ?
MFH-ino NWDhfmpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nGfmlEPTB;MT62OkBvVQ>? NV6wXYJGW0GQR1XS
Calu-6 M1[zNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTFwN{Ogcm0> MWDTRW5ITVJ?
HEL NF:3TI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HzZWlEPTB;MT63PUBvVQ>? MmXKV2FPT0WU
CAL-33 NVnJ[HRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTGUZhPUUN3ME2xMlg6KG6P M4r5c3NCVkeHUh?=
HSC-3 M2Ljfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwOUGgcm0> NVrCVYNzW0GQR1XS
KU812 NIDKO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK5VolGUUN3ME2xMlkyKG6P NGqxZZFUSU6JRWK=
EB2 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK2c5d1UUN3ME2yMlAyKG6P M364[HNCVkeHUh?=
SR MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nDfmlEPTB;Mj6xNkBvVQ>? MXvTRW5ITVJ?
NCI-H2087 M37MZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJwMUSgcm0> MWLTRW5ITVJ?
H4 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn65TWM2OD1{LkG4JI5O MY\TRW5ITVJ?
EW-1 M3rJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjFdYV1UUN3ME2yMlIzKG6P NFHLW2JUSU6JRWK=
MC-IXC MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJwMk[gcm0> MoXzV2FPT0WU
NCI-H727 M2\vcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T5WWlEPTB;Mj61NUBvVQ>? NV3UdGp6W0GQR1XS
MRK-nu-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLpTWM2OD1{LkW3JI5O MonVV2FPT0WU
COLO-668 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;IZVNkUUN3ME2yMlY3KG6P MWLTRW5ITVJ?
CGTH-W-1 NUDlcop5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[2XmZKSzVyPUKuO|Ihdk1? NYjJTVBuW0GQR1XS
CHP-212 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGKxXndKSzVyPUKuO|Uhdk1? NF\RRWtUSU6JRWK=
GI-1 M1Tzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3Je|RKSzVyPUKuO|Yhdk1? NV;nbop2W0GQR1XS
HCC1806 M375fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXXOJJ{UUN3ME2yMlkyKG6P Mn7tV2FPT0WU
HLE M{DEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXvTWM2OD1|IH7N NUHBPHJSW0GQR1XS
HSC-2 NFPpZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorsTWM2OD1|LkCzJI5O M1rr[3NCVkeHUh?=
DMS-273 NYnueI52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnxdGFKSzVyPUOuNFchdk1? M1TjWnNCVkeHUh?=
DU-4475 M1q2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNwMUSgcm0> MVrTRW5ITVJ?
LXF-289 NWfRUo83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:5d25KSzVyPUOuN|Ehdk1? M2jsSnNCVkeHUh?=
PANC-03-27 M3nrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi3N2VKSzVyPUOuOVEhdk1? MkfNV2FPT0WU
GAMG NVfvenhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNwN{Sgcm0> MoK4V2FPT0WU
NCI-H522 NXLReVB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3ySXR4UUN3ME20MlM1KG6P MYPTRW5ITVJ?
SW626 MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP4TWM2OD12LkS2JI5O MYjTRW5ITVJ?
HT-144 NUG3R2ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTOb|ViUUN3ME20MlkzKG6P NHO3WnBUSU6JRWK=
MEL-HO MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke2TWM2OD13LkG2JI5O MUfTRW5ITVJ?
BE-13 M2q3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv1PINKSzVyPUWuNlEhdk1? NGjRW5RUSU6JRWK=
VA-ES-BJ NW\neZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTVwMk[gcm0> MXfTRW5ITVJ?
NCI-H441 NVfHeZJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTITWM2OD13Lk[gcm0> MYLTRW5ITVJ?
KP-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ftW2lEPTB;NT62NUBvVQ>? NUnJe4Y6W0GQR1XS
LoVo MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTVwN{Ggcm0> NEPp[mlUSU6JRWK=
HT-1080 NUfqOW1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHpUmxKSzVyPUWuPFMhdk1? MnP3V2FPT0WU
GB-1 NY\ifGwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG1WINKSzVyPUWuPFQhdk1? MVrTRW5ITVJ?
IA-LM M4PUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;lfpdKSzVyPUWuPVEhdk1? NFnPO5dUSU6JRWK=
8-MG-BA NV7Ve4JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\m[2FnUUN3ME21Mlk{KG6P NGHOTIdUSU6JRWK=
SK-HEP-1 NVm4WY1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rHPWlEPTB;Nj6xOEBvVQ>? Ml2zV2FPT0WU
697 M3PvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljwTWM2OD14LkK1JI5O MYnTRW5ITVJ?
KYSE-450 NWXoRmZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTZwM{Kgcm0> MnPXV2FPT0WU
HCC2998 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;kdZhKSzVyPU[uN|Qhdk1? M4TvOXNCVkeHUh?=
HD-MY-Z NYrQOXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUexe2N7UUN3ME22MlY5KG6P MoDqV2FPT0WU
OS-RC-2 M1fxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvnTWM2OD14Lk[4JI5O MXvTRW5ITVJ?
SF126 NFPEdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC1TWM2OD15LkC1JI5O M4i4XHNCVkeHUh?=
Ca-Ski NYDQTZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTdwMEmgcm0> NU\Z[GJmW0GQR1XS
NCI-H358 Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfxXoJKSzVyPUeuNVYhdk1? MW\TRW5ITVJ?
J82 M2PjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PKSmlEPTB;Nz60NUBvVQ>? MYPTRW5ITVJ?
NCI-H2342 M172XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFywRYtKSzVyPUeuOlMhdk1? MUTTRW5ITVJ?
OVCAR-8 MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi0cZhKSzVyPUeuPUBvVQ>? M2r0THNCVkeHUh?=
TE-8 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz5[oZHUUN3ME24JI5O NV;kfZA3W0GQR1XS
ETK-1 NY\WNXlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrjR3pYUUN3ME24MlA5KG6P NWXVNG5nW0GQR1XS
HAL-01 Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\a[GlEPTB;OD6yJI5O NGPR[XZUSU6JRWK=
KYSE-150 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H2N2lEPTB;OD60O{BvVQ>? NGC0W2pUSU6JRWK=
NCI-H810 M2jD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n5PGlEPTB;OD61OkBvVQ>? MnT2V2FPT0WU
ONS-76 NIqweoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRThwNkigcm0> M3;3d3NCVkeHUh?=
NMC-G1 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16zfmlEPTB;OD63OkBvVQ>? M2\rcnNCVkeHUh?=
C3A NXTS[GVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ryOmlEPTB;OD64OEBvVQ>? M{TXUXNCVkeHUh?=
PA-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRThwOUmgcm0> M{TzW3NCVkeHUh?=
SH-4 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S3UGlEPTB;OT6wNkBvVQ>? NX;VeVlxW0GQR1XS
EFO-27 NHnqOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHKTWM2OD17LkC1JI5O NVrNVZY2W0GQR1XS
CAPAN-1 NV3vR3Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTlwMkOgcm0> M2HGNXNCVkeHUh?=
DU-145 M4racWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u0Z2lEPTB;OT6yPUBvVQ>? NUC5UHNHW0GQR1XS
A101D M{nVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTlwM{egcm0> NXfJfpExW0GQR1XS
ST486 M1XsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7mTWM2OD17LkSxJI5O NX3K[ZV7W0GQR1XS
NCI-H1437 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DDdWlEPTB;OT60NkBvVQ>? M4PxbXNCVkeHUh?=
HGC-27 NETtSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrIZYlKSzVyPUmuOkBvVQ>? NEXQSIRUSU6JRWK=
8305C NXz4UVU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTVTWM2OD17Lk[0JI5O NVPoT4FVW0GQR1XS
OCUB-M MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPpbYhKSzVyPUGwMlA{KG6P MXnTRW5ITVJ?
COLO-679 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFyLkC3JI5O M4DBWnNCVkeHUh?=
Detroit562 NHzyW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\1dGlEPTB;MUCuOFIhdk1? M1n1bnNCVkeHUh?=
A204 NUX1WGxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDRe2tYUUN3ME2xNU4yPiCwTR?= NITwdWJUSU6JRWK=
NCI-H1734 NFzyXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTFzLkK5JI5O Mmj3V2FPT0WU
MC-CAR MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFzLkW4JI5O M{SxRnNCVkeHUh?=
NCI-H2170 Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFzLkm3JI5O M{TrWXNCVkeHUh?=
NCI-SNU-5 NIK4UFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF{LkGzJI5O NFPTb3JUSU6JRWK=
HCE-T NGHkTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzjTWM2OD1zMj60NkBvVQ>? M17VfnNCVkeHUh?=
KYSE-180 NHHuco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nObWlEPTB;MUKuPFEhdk1? M2Dzc3NCVkeHUh?=
C8166 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n0[GlEPTB;MUOuNFghdk1? MoHQV2FPT0WU
NCI-H460 NIjD[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjrTWM2OD1zMz61OEBvVQ>? Mny3V2FPT0WU
SNU-449 Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF|Lke3JI5O NVn3eVh{W0GQR1XS
MDA-MB-468 MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInVXHBKSzVyPUG0MlEzKG6P NV;0cVBIW0GQR1XS
COR-L23 NYLFNXJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M171OmlEPTB;MUSuNVMhdk1? MnzMV2FPT0WU
CTV-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF2LkG0JI5O NX;nXJU5W0GQR1XS
BL-41 NX;oO5RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF2LkO3JI5O MYLTRW5ITVJ?
IGR-1 M{HEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL3SGdKSzVyPUG0MlQzKG6P NXTnXoo3W0GQR1XS
TK10 NWHzO5BYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LBO2lEPTB;MUSuOFkhdk1? NYHTfWNSW0GQR1XS
REH MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3adGNKSzVyPUG0MlUyKG6P M4PaVnNCVkeHUh?=
LU-139 NIq3N2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF2LkW5JI5O NWLZRWhiW0GQR1XS
KP-N-YS MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXLNWNKSzVyPUG0Mlk4KG6P MlXxV2FPT0WU
PANC-10-05 M2[1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDlTWM2OD1zNT6zPEBvVQ>? M{WxS3NCVkeHUh?=
HL-60 M2KzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX4cZZKSzVyPUG1MlY6KG6P M2Ps[nNCVkeHUh?=
T84 NXvrR2Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETsdY5KSzVyPUG1Mlk3KG6P MWXTRW5ITVJ?
RPMI-8226 M1Hyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnhVIpWUUN3ME2xOk4xOiCwTR?= MXXTRW5ITVJ?
UM-UC-3 Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XMW2lEPTB;MU[uNVYhdk1? NH;zeFJUSU6JRWK=
TE-10 M4i0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Xj[GlEPTB;MU[uNlEhdk1? NYDYWIdyW0GQR1XS
CAL-148 MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TGW2lEPTB;MUeuNlMhdk1? NIrCfpJUSU6JRWK=
BV-173 NFi2XZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInpVIVKSzVyPUG3MlI4KG6P M37qUXNCVkeHUh?=
Calu-3 NEe2Tm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS1fFB{UUN3ME2xO{4zQSCwTR?= NUDqZ|lGW0GQR1XS
RPMI-2650 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TuUmlEPTB;MUeuOVkhdk1? M171enNCVkeHUh?=
MKN45 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPuS5NbUUN3ME2xO{44OyCwTR?= MV;TRW5ITVJ?
NUGC-3 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPQTWM2OD1zOD6zOEBvVQ>? M2TCTHNCVkeHUh?=
NCI-H520 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\sSWlEPTB;MUiuO|chdk1? NVvySI83W0GQR1XS
CCRF-CEM Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP0TWM2OD1zOD64OUBvVQ>? NWraNlYzW0GQR1XS
NCI-H2405 MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTLT5lIUUN3ME2xPU4yKG6P NGrwb4pUSU6JRWK=
ES7 NFv2UXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnQTWM2OD1zOT63OkBvVQ>? MWTTRW5ITVJ?
BPH-1 NWXDZmNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLaTWM2OD1{MD6yPEBvVQ>? MYXTRW5ITVJ?
SAS NHvaWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHOTWM2OD1{MD61JI5O M{DVW3NCVkeHUh?=
HuCCT1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDjTWM2OD1{MD61PEBvVQ>? NWDORVVFW0GQR1XS
LOUCY M2XqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJyLk[2JI5O M3nOU3NCVkeHUh?=
NCI-H292 NETW[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHTelVvUUN3ME2yNE44QSCwTR?= MXrTRW5ITVJ?
G-361 NFjaUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJzLkC3JI5O MYDTRW5ITVJ?
M059J MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjmc|VTUUN3ME2yNU4xQCCwTR?= M2rYVnNCVkeHUh?=
NCI-H1651 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\nZ49KSzVyPUKxMlEyKG6P MX\TRW5ITVJ?
KALS-1 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG3TWM2OD1{MT6zPUBvVQ>? NULrfHllW0GQR1XS
DJM-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfhTJlXUUN3ME2yNU42QSCwTR?= MmPrV2FPT0WU
AU565 NEDHeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXIfHRoUUN3ME2yNU45OyCwTR?= NUS2T|lSW0GQR1XS
HCC38 M37G[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTTPVBKSzVyPUKxMlk2KG6P MYTTRW5ITVJ?
U251 NFfLRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LPfmlEPTB;MkKuNlchdk1? NETpNlBUSU6JRWK=
ABC-1 M33UbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrSTWM2OD1{Mj62OUBvVQ>? MWrTRW5ITVJ?
SK-NEP-1 M3O4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LlXWlEPTB;MkKuPVMhdk1? MYXTRW5ITVJ?
CESS M3;6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHwTWM2OD1{Mz6xPUBvVQ>? NFHD[4dUSU6JRWK=
MIA-PaCa-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPpWmFLUUN3ME2yN{4{PiCwTR?= NVXuUpNvW0GQR1XS
SUP-T1 NYXje3ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDUTWM2OD1{Mz60O{BvVQ>? MWXTRW5ITVJ?
L-428 NViyV49JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJ|Lk[yJI5O NHWwToxUSU6JRWK=
SW954 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf2TWM2OD1{Mz62PEBvVQ>? MXXTRW5ITVJ?
HO-1-N-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX1TGV1UUN3ME2yN{44PyCwTR?= Mo[zV2FPT0WU
CHP-126 NEe1UI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS1OmY6UUN3ME2yOE4yPCCwTR?= M{nUbHNCVkeHUh?=
HMV-II MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f4ZmlEPTB;MkSuN|Qhdk1? MmrHV2FPT0WU
NB10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPPeXBKSzVyPUK0MlM4KG6P NGDOfllUSU6JRWK=
A172 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fDemlEPTB;MkSuO|Ehdk1? NEO1WXdUSU6JRWK=
MONO-MAC-6 MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ2Lki0JI5O M4fqcXNCVkeHUh?=
NCI-H1650 NW\iO3lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHSbFVVUUN3ME2yOU41KG6P M3i4NXNCVkeHUh?=
NH-12 NH\M[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnraTWM2OD1{NT61JI5O MVnTRW5ITVJ?
ML-2 NXv6UWU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjVTWM2OD1{NT63OEBvVQ>? MkHoV2FPT0WU
MZ2-MEL MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\UTWM2OD1{Nj6yNkBvVQ>? Mn\lV2FPT0WU
COLO-684 NITYXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPFTWM2OD1{Nj60NUBvVQ>? NFHRNYtUSU6JRWK=
HuP-T4 NFfJZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TFTGlEPTB;MkeuN{BvVQ>? MlfEV2FPT0WU
SW837 MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C4T2lEPTB;MkeuOlIhdk1? NWnNcnhGW0GQR1XS
MDA-MB-231 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnyyTWM2OD1{Nz63PEBvVQ>? MV\TRW5ITVJ?
KYSE-140 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJ5LkmxJI5O M4nWcnNCVkeHUh?=
NOMO-1 M2rFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;nUmNKSzVyPUK4MlY5KG6P MUDTRW5ITVJ?
GP5d NHfOZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3TTWM2OD1{OD63NkBvVQ>? M4TWS3NCVkeHUh?=
COR-L105 NFftbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn61TWM2OD1{OT60NkBvVQ>? NUX6O45oW0GQR1XS
LS-411N MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrJe4lKSzVyPUK5Mlg5KG6P MV7TRW5ITVJ?
NY MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTGR4c1UUN3ME2zNE4yQCCwTR?= NGPoR49USU6JRWK=
NCI-H2030 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGyTWM2OD1|MD60OUBvVQ>? M{[yNHNCVkeHUh?=
CCF-STTG1 NXfGOIxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zibGlEPTB;M{GuOFIhdk1? MlS1V2FPT0WU
NCI-H1703 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNzLke4JI5O MV7TRW5ITVJ?
TUR MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTN{LkCzJI5O MYDTRW5ITVJ?
NOS-1 NF3xbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml64TWM2OD1|Mj60OEBvVQ>? NUSwbFdrW0GQR1XS
A2058 NFnhTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTN{LkizJI5O M4TKdXNCVkeHUh?=
LCLC-103H MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV65c2tKUUN3ME2zN{4zPSCwTR?= NIPTPI5USU6JRWK=
NCI-H510A MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvSW4dKSzVyPUOzMlI4KG6P MoXrV2FPT0WU
BC-1 M2TuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTN|Lke3JI5O NVX5UnZsW0GQR1XS
SK-CO-1 NUHPepMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3hTIdKSzVyPUO0MlAyKG6P M2HQNXNCVkeHUh?=
A673 MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7VXmlpUUN3ME2zOE4yPyCwTR?= NYO3cFJQW0GQR1XS
VM-CUB-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHG0VVFKSzVyPUO0MlY6KG6P M4\W[3NCVkeHUh?=
HH M1fHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN3LkC2JI5O NVv1botpW0GQR1XS
CAL-27 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLxepZKSzVyPUO1MlE3KG6P MXnTRW5ITVJ?
NEC8 M2fySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTVUJJKSzVyPUO1MlM4KG6P MnjwV2FPT0WU
BxPC-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P2T2lEPTB;M{[uPVEhdk1? NXzGXJU{W0GQR1XS
SNB75 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyyZpdKSzVyPUO3MlI1KG6P NGO3dXRUSU6JRWK=
NB13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTN6LkKzJI5O MoLQV2FPT0WU
SK-OV-3 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj2Xm1KSzVyPUO4Mlc1KG6P MW\TRW5ITVJ?
ME-180 NXGzRZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rESmlEPTB;M{iuPEBvVQ>? NXu3ZlBbW0GQR1XS
JiyoyeP-2003 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrQT481UUN3ME2zPU4{QCCwTR?= MXnTRW5ITVJ?
LU-134-A NYLSTlliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfCTWM2OD12MD6wNkBvVQ>? MknSV2FPT0WU
LS-123 M1qxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTRyLkK4JI5O MWPTRW5ITVJ?
COLO-800 NFv3Z5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XjOmlEPTB;NECuOVYhdk1? MVvTRW5ITVJ?
LB831-BLC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHkTWM2OD12MT64OUBvVQ>? MlXmV2FPT0WU
NCI-H747 NUG4VoV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWiwOpJZUUN3ME20Nk4zQCCwTR?= M2TuS3NCVkeHUh?=
MZ7-mel MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X6RWlEPTB;NEKuOlYhdk1? M2mxU3NCVkeHUh?=
GT3TKB NXP2dnJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TUSmlEPTB;NEKuO|Ihdk1? MkLhV2FPT0WU
MOLT-16 NFrkNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTR|LkC1JI5O M3i0[3NCVkeHUh?=
23132-87 NXy4RWFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTR|LkC1JI5O M1r4TXNCVkeHUh?=
PF-382 M4XtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jRVGlEPTB;NESuNlIhdk1? M3TpRXNCVkeHUh?=
ES3 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTR2Lk[gcm0> NHfjNHRUSU6JRWK=
SW756 M3fkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjpTWM2OD12NT6xOEBvVQ>? M{K3[HNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro Water 16 mg/mL (60.79 mM) warming
DMSO 15 mg/mL (56.99 mM)
Ethanol <1 mg/mL
In vivo water warming 16mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02538432 Not yet recruiting Prostate Cancer|Non-Small Cell Lung Cancer|Breast Cancer University of Maryland January 2017 Phase 2
NCT02767557 Not yet recruiting Unresectable Pancreatic Carcinoma Herlev Hospital|Celgene|Roche Pharma AG October 2016 Phase 2
NCT02806687 Not yet recruiting Pancreatic Adenocarcinoma University Hospital, Toulouse|BIOTHERAPY department of the clinical center of investigation- CIC 1436, Toulouse|InvivoGen Therapeutics October 2016 Phase 2
NCT02741388 Not yet recruiting B-cell Lymphoma The Lymphoma Academic Research Organisation|Karyopharm Therapeutics, Inc September 2016 Phase 1
NCT02723838 Not yet recruiting Muscle-invasive Transitional Cell Carcinoma of the Bladder Oncolytics Biotech September 2016 Phase 1
NCT02767752 Not yet recruiting Pancreatic Cancer Herlev Hospital|GENIS September 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID